PLCB1 and asthma: As recommended by Global Initiative for Asthma (GINA) guideline, LABA should not be used as monotherapy in asthma, because ICS has been reported to not only suppress airway inflammation and hyperreactivity, however, it also prevent LABA induced down-regulation of β2AR and recover their sensitivity, thus may lead to increase of M3R, PLC-β1, and IP3 expression as demonstrated by McGraw9, 43.